Global sales of influenza vaccines and therapeutics have been witnessing rapid growth after their approval

Date: 25 May 2017

Over the recent years, the global influenza market has been growing rapidly as the global sales of vaccines and therapeutics have been witnessing rapid growth after their approval. Globally, the growth in the influenza market is driven by increasing awareness regarding influenza owing to the rise in global incidences of the disease. Mounting threat of bioterrorism is another factor backing the growth in the market.

According to Azoth Analytics research report, “GlobalInfluenza Drugs and Vaccines Market – By Drugs (Zanamivir, OseltamivirPhosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) - Analysis ByRegion, By Country: Opportunities and Forecast (2016-2021) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan)”, global market is projected to display a robust growth represented by a CAGR of 10.24% during 2016 – 2021, chiefly driven by large number of global occurrences of influenza and the World Health Organization’s initiatives to inhibit its growth through mass preparedness. 

Globally, annual epidemics of influenza resulted in about 3 to 5 million cases of severe illness and about 250,000 to 500,000 deaths. Approval and successful commercialization of influenza therapeutics such as Relenza, Tamiflu etc. have made the biopharmaceutical industry realise the immense potential that this market holds. Moreover, there has been heavy investment in the development of influenza vaccines such as ‘Trivalent’ and ‘Quadrivalent’ by leading biotechnology and biopharmaceutical companies which presently protect against three and four respectively. Several other molecules are currently in late stage of clinical trials and are expected to gain approval and enter market in next few years which will result in heavy growth of global influenza market. Major trend that the global influenza market has been witnessing over the years is development of manufacturing systems based on plants, bacteria, yeast and other cell cultures.  

Among the drugs, trivalent and quadrivalent vaccines will witness faster growth than therapeutics such as Rapivab, Tamiflu etc. in the forecasted period. Among the regions, North America is anticipated to hold the highest share in the market, mainly driven by increasing government expenditure over the development of new drugs and vaccines.

The report titled “GlobalInfluenza Drugs and Vaccines Market – By Drugs (Zanamivir, OseltamivirPhosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) - Analysis ByRegion, By Country: Opportunities and Forecast (2016-2021) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan)”, has covered and analysed the potential of Global Influenza Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global influenza market. Additionally, the report also highlights market entry strategies for various companies across the globe.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Influenza Market on the basis of Analysis By Product Type (Therapeutics and Vaccines), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., France, China and India).

...